Zhejiang Starry Pharm Co Ltd Market Cap ($524.77 Million)
Market Cap & Net Worth: Zhejiang Starry Pharm Co Ltd (603520)
Zhejiang Starry Pharm Co Ltd market cap. Zhejiang Starry Pharm Co Ltd (SHG:603520) has a market capitalization of $524.77 Million (CN¥3.59 Billion) as of November 8, 2026. Listed on the SHG stock exchange, this China-based company holds position #11625 globally and #3296 in its home market, demonstrating a 2.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Zhejiang Starry Pharm Co Ltd's stock price CN¥8.18 by its total outstanding shares 438409881 (438.41 Million). Also see cash efficiency ratio of Zhejiang Starry Pharm Co Ltd for how efficiently the company converts equity into cash flow.
Zhejiang Starry Pharm Co Ltd Market Cap History (2016–2026)
Zhejiang Starry Pharm Co Ltd market cap history from 2016 to 2026. Data shows growth from $1.03 Billion to $524.77 Million (3.27% CAGR). Check 603520 stock price for real-time trading data and today's change.
Zhejiang Starry Pharm Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Zhejiang Starry Pharm Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore net asset growth rate of Zhejiang Starry Pharm Co Ltd to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.25x
Zhejiang Starry Pharm Co Ltd's market cap is 0.25 times its annual revenue
Latest Price to Earnings (P/E) Ratio
58.96x
Zhejiang Starry Pharm Co Ltd's market cap is 58.96 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $1.03 Billion | $672.95 Million | $76.12 Million | 1.53x | 13.49x |
| 2017 | $626.56 Million | $710.94 Million | $83.12 Million | 0.88x | 7.54x |
| 2018 | $584.57 Million | $890.47 Million | $93.68 Million | 0.66x | 6.24x |
| 2019 | $1.33 Billion | $1.31 Billion | $170.33 Million | 1.02x | 7.84x |
| 2020 | $2.91 Billion | $1.37 Billion | $238.73 Million | 2.13x | 12.19x |
| 2021 | $2.89 Billion | $2.00 Billion | $323.75 Million | 1.45x | 8.94x |
| 2022 | $1.24 Billion | $2.13 Billion | -$75.85 Million | 0.58x | N/A |
| 2023 | $903.28 Million | $2.20 Billion | $44.23 Million | 0.41x | 20.42x |
| 2024 | $557.49 Million | $2.35 Billion | -$49.10 Million | 0.24x | N/A |
| 2025 | $603.04 Million | $2.45 Billion | $10.23 Million | 0.25x | 58.96x |
Competitor Companies of 603520 by Market Capitalization
Companies near Zhejiang Starry Pharm Co Ltd in the global market cap rankings as of November 8, 2026. Also see Zhejiang Starry Pharm Co Ltd asset portfolio for a full breakdown of the balance sheet.
Key companies related to Zhejiang Starry Pharm Co Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #511 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #530 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #567 globally with a market cap of $47.07 Billion USD ( CN¥321.69 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #609 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #511 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #530 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $46.61 |
| #567 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $47.07 Billion | CN¥50.43 |
| #609 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €18.80 |
Market Capitalization of Zhejiang Starry Pharm Co Ltd (2016–2026)
Market capitalization of Zhejiang Starry Pharm Co Ltd from 2016 to today. Between 2016 and today, Zhejiang Starry Pharm Co Ltd's market cap moved from $1.03 Billion to $ 524.77 Million, with a yearly change of 3.27%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥524.77 Million | -12.98% |
| 2025 | CN¥603.04 Million | +8.17% |
| 2024 | CN¥557.49 Million | -38.28% |
| 2023 | CN¥903.28 Million | -27.16% |
| 2022 | CN¥1.24 Billion | -57.15% |
| 2021 | CN¥2.89 Billion | -0.60% |
| 2020 | CN¥2.91 Billion | +118.07% |
| 2019 | CN¥1.33 Billion | +128.37% |
| 2018 | CN¥584.57 Million | -6.70% |
| 2017 | CN¥626.56 Million | -38.96% |
| 2016 | CN¥1.03 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 8th, 2026 the market cap of Zhejiang Starry Pharm Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $524.77 Million USD |
| MoneyControl | $524.77 Million USD |
| MarketWatch | $524.77 Million USD |
| marketcap.company | $524.77 Million USD |
| Reuters | $524.77 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Zhejiang Starry Pharm Co Ltd
Zhejiang Starry Pharmaceutical Co.,Ltd., together with its subsidiaries, engages in the research, development, production, and sale of pharmaceutical raw materials in China and internationally. It operates through Contrast Agent Series, Quinolone Series, CMO/CDMO, and Others segments. The company offers preparation products comprising iohexol, iopamidol, iodixanol, iomeprol, ioversol, and gadoben… Read more